Four biotech IPOs raised $1.5B in April, the biggest month in more than five years, according to Renaissance Capital. Hemab Therapeutics and Seaport Therapeutics joined the public markets with upsized deals, signaling continued investor appetite for early-stage biopharma. The increase in proceeds follows a quieter period for new listings, and it matters for deal-making because IPO calendars can affect how aggressively venture and crossover funds allocate capital. For emerging therapeutic platform companies, fresh public-market liquidity can also improve follow-on financing options. While the articles do not provide valuation details, the scale of April’s fundraising points to improving conditions for biotech issuers seeking growth capital without waiting for later clinical readouts. Market participants will likely focus next on post-listing performance and how quickly these newly public companies convert funding into clinical milestones.